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Abstract
Central nervous system (CNS) malignancies contribute significantly to the 
global burden of cancer. Brain tumors constitute the most common solid organ 
tumors in children and the second most common malignancies of childhood 
overall. Accounting for nearly 20% of all pediatric malignancies, these are the 
foremost cause of cancer-related deaths in children 0–14 years of age. This book 
chapter provides a state-of-the-art overview of pediatric brain tumors. It discusses 
their morbidity and mortality and introduces the WHO 2021 classification of CNS 
tumors, which is critical to therapeutic decision-making. It then describes the 
modern understanding of tumor grading and its clinical implications, followed by 
the general principles of diagnosis and management. The chapter then discusses, 
in detail, those brain tumors which have the highest disease burden in children, 
including medulloblastoma, astrocytoma, ependymoma, schwannoma, menin-
gioma, amongst others. The landscape of treatment of pediatric brain tumors has 
been rapidly evolving, with several effective therapies on the horizon.
Keywords: CNS tumor, oncology, neuro-oncology, pediatric oncology, malignancy, 
neurology, neurosurgery, neuroradiology, brain tumor
1. Introduction
Central nervous system (CNS) malignancies contribute significantly to the 
global burden of cancer. The average annual age-adjusted incidence rate (AAAIR) 
of all CNS tumors, as estimated in the US population was 23.79 according to 
the most recent report of the Central Brain Tumor Registry of the United States 
(CBTRUS) [1]. Amongst individuals aged 15–39 years, CNS tumors constitute the 
third most common tumor overall, while amongst individuals aged 40 and above, 
they are the third most common cause of cancer death.
Brain tumors find an overwhelmingly high representation in the pediatric age group. 
They constitute the most common solid organ tumors in children and the second most 
common malignancies of childhood overall, accounting for nearly 20% of all pediatric 
malignancies [1]. The CBTRUS 2020 report estimated that the AAAIR of CNS tumors 
amongst children aged 0 to 14 was 5.83 per 100,000 individuals. The annual age-
adjusted mortality rate (AAAMR) of CNS tumors in this age group was determined to 
be 0.71 per 100,000, leading to brain tumors being the biggest cause of cancer death 
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amongst 0 to 14 years of age. Despite the advances of the last few decades in imaging, 
molecular diagnostics, surgical techniques, and adjuvant therapy, unfortunately, less 
than required improvement has occurred in rates of survival in the pediatric age group.
Girardi et al., in a systematic review published in 2019, determined that little 
data from low and low-middle-income countries (LMICs) is available regarding 
long-term survival from pediatric brain tumors [2]. This sobering data stands 
amidst the backdrop of studies demonstrating that the nations with lower economic 
development deliver a significantly poorer quality of care [3].
Adult survivors of pediatric brain tumors face significant challenges. Several 
factors come together to drastically impact their neurocognitive and psychosocial out-
comes. These include but are not limited to, the clinical features of the tumor itself, 
its treatment especially radiotherapy to a developing brain, access to support systems 
and quality of rehabilitative services, individual factors, amongst others [4].
The pediatric landscape is significantly different from the adult landscape with 
regard to brain tumors. Pediatric brain tumors have differing common sites of 
origin, histology, genetics, which lend themselves to dissimilar diagnostic and thera-
peutic considerations. As a rule of thumb, two-thirds of tumors in adults arise from 
sites above the tentorium cerebelli, while two-thirds of tumors in children arise from 
structures below the tentorium cerebelli. Several genetic syndromes also include 
pediatric brain tumors as one of their clinical manifestations. These include but are 
not limited to tuberous sclerosis, Li-Fraumeni syndrome, Turcot syndrome, Type 1 
and 2 Neurofibromatosis, Gorlin syndrome, Cowden syndrome, amongst others.
Brain tumors that have the highest disease burden in children include medul-
loblastomas, astrocytomas, ependymomas, schwannomas, meningiomas, amongst 
others. Their details, along with their specific epidemiology, will be discussed in 
greater depth in further sections.
2. Classifying brain tumors: an evolving paradigm
The classification of tumors in the central nervous system (CNS) is the critical 
factor driving treatment decisions, given the wide variation amongst different 
tumors in response to each anti-cancer modality. For instance, some like midline 
pontine gliomas do not respond well to chemotherapy and are only partially ame-
nable to radiotherapy.
Several classification schemas for CNS tumors exist. These range from those 
solely based on histology alone to those relying primarily on genetic and epigenetic 
features. While microscopic diagnosis finds utility in its low cost and accessibility, 
its insufficiently high inter-rater reliability along with the advancements in molecu-
lar biology have led to it not being the sole basis for classification [5].
Other simpler classification systems divide tumors based on the major site of 
origin. Supratentorial tumors are those which are located above the tentorium 
cerebelli and therefore may involve cerebral hemispheres. In children, these com-
monly include high-grade gliomas, low-grade gliomas, embryonal tumors, atypi-
cal teratoid/rhabdoid tumors, meningiomas, choroid plexus tumors, and pineal 
tumors. In contrast, infratentorial tumors are located below the tentorium and, 
therefore, originate from the brainstem, the cerebellum, and the 4th ventricle. In 
children, these commonly include medulloblastomas, cerebellar astrocytomas, 
ependymomas, brainstem gliomas, atypical teratoid/rhabdoid tumors, and rarely 
choroid plexus tumors. The sellar region is a region at the base of the skull around 
the sella turcica where the major tumors of note in children include pituitary adeno-
mas, craniopharyngiomas, gliomas, and germ cell tumors.
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3. The WHO 2021 classification of CNS tumors
The World Health Organization (WHO) has developed and published updated 
versions of the most widely used classification system for CNS tumors for decades. 
The WHO 2007 classification schema was the last iteration to primarily be based 
on histology [6]. Very recently, the WHO 2021 classification (WHO CNS5) has 
been published, which functions as an integrated histo-molecular classification 
system [7].
3.1 Key updates in the WHO 2021 classification
The WHO CNS5 classification, a broad overview of which is given in Figure 1, 
adheres to the landmark recommendations made by the cIMPACT-NOW group, 
especially the ones made at the Utrecht Meeting in 2019. The Consortium to Inform 
Molecular and Practical Approaches to CNS Tumor Taxonomy—Not Official WHO 
(cIMPACT-NOW) is an influential group of neuro-oncologists and neuropatholo-
gists which was established in 2016 to provide recommendations regarding the 
upcoming WHO classification [8]. Based on the cIMPACT-NOW recommendations, 
WHO CNS5 makes new categories, merges a few ones, and introduces new entities. 
These updates include the following:
I. Greater integration of histology has been done with immunohistochemical, 
ultrastructural, and molecular features of tumors.
II. Arabic numerals (1, 2, 3, and 4) for tumor grade have replaced Roman 
numerals (I, II, III, and IV) to have CNS tumor grading consistent with other 
systems and prevent typographical errors.
III. Grading of tumors is to be done within tumor types (rather than across dif-
ferent tumor types).
IV. Gliomas have been separated into pediatric-type and adult-type, with several 
subcategories. This change carries several key clinical implications.
V. The term ‘glioblastoma’ is reserved for IDH wild-type tumors and only refers 
to grade 4 tumors
VI. IDH-mutant astrocytoma will be graded based on histo-molecular  
features
VII. Layered reporting of medulloblastoma is recommended:
a. Integrated Diagnosis (combining histology and biology)
b. Histological Diagnosis
c. CNS WHO Grade
d. Molecular Information
VIII. Ependymomas have new sub-categories including Posterior Fossa A 
Ependymoma, Posterior Fossa B type Ependymoma, etc.
CNS Malignancies
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3.2 Modern understanding of tumor grading and its clinical implications
CNS tumor grading has been long-known to be linked closely with clinical-
biological features, and this has been augmented with recent works in genomics and 
Figure 1. 
A broad overview of the World Health Organization (WHO) 2021 classification of central nervous system 
(CNS) tumors. This original figure has been drawn from [34], published online ahead of print, 2021 Jun 29, 
noab106, where the full classification is available.
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methylomics. Tumor grading guides treatment decisions and the four WHO tumor 
grades have been historically essential in determining prognosis.
Previously, WHO used to assign a grade to one tumor type (e.g. anaplastic 
astrocytoma to grade 3), and grading was done across tumor types. With WHO 
CNS5, this has been radically shifted to grading within tumor types, similar to non-
CNS tumors where the latter had been the norm for decades. This approach, while 
enhancing flexibility while grading, also highlights the pathobiological similarities 
within tumor types, rather than simply trying to crudely approximate clinical 
behavior across entities [7].
The current grading paradigm is a combination of histological and molecular 
featusres, rather than solely being based on microscopic features alone. Key 
examples of this are reflected in the Update 3 and 5 of cIMPACT-NOW [8]. The 
newly introduced integrated grading system continues to retain some features from 
prior WHO classification editions. For instance, meningiomas can only go from 
grade 1–3, and therefore it is not possible to have a ‘CNS WHO Grade 4 Meningioma’. 
Additionally, because these malignancies were traditionally graded based on their 
natural history as well, therefore, current therapeutic options lead to a conflict 
between the grade and the expected outcome. For instance, a medulloblastoma can 
be assigned a CNS WHO grade 4, yet a WNT-activated medulloblastoma has good 
survival outcomes when given effective therapies [7].
4. Clinical features of pediatric brain tumors
Pediatric brain tumors are usually suspected based on their specific clinical fea-
tures. Details regarding the clinical presentation of some common tumors are given 
in their respective sections. However, in general, these tumors find their manifesta-
tion in two major ways, one due to raised intracranial pressure, and the other due to 
the specific location of the tumor involving adjacent neural structures [9].
In children, raised intracranial pressure may be due to the tumor mass itself, or 
secondary to hydrocephalus, or maybe a consequence of cerebral edema. Acutely, 
this may manifest as headache, nausea and vomiting, altered sensorium, irritabil-
ity, papilledema, hypertension, abnormal breathing, seizures, etc. In the long-
term, this may manifest as macrocephaly, loss of appetite, delayed psychomotor 
development, personality changes, etc. [10].
Brain tumors also may manifest through the involvement of adjacent structures. 
Focal neurological deficits such as arm or leg weakness in case of cerebral tumors, 
ataxia and torticollis in posterior fossa tumors, endocrinopathies such as preco-
cious puberty, obesity in case of sellar/parasellar tumors, vision impairment due to 
cranial nerve involvement, etc. [10].
5. Principles of diagnosis and treatment of pediatric brain tumors
An experienced, multidisciplinary team is essential for the management of pedi-
atric CNS tumors, consisting of pediatrician, neuro-radiologist, neuro-oncologist, 
neurosurgeon, radiation oncologist, physiatrist, and other ancillary services.
5.1 Diagnosis
Brain imaging is the mainstay of diagnosis. Computed tomography (CT) and 
magnetic resonance (MR) imaging are both often required. While the former allows 
a better assessment of bony involvement and tumoral calcifications, the latter helps 
CNS Malignancies
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to closely delineate the tumor and the involved anatomy of the region, along with 
helping predict the type of tumor. MR imaging with gadolinium contrast is often 
the single most valuable diagnostic test for CNS tumors.
MR Angiography (MRA) is useful for visualizing blood vessels, which helps 
determine the surgical approach. MR Spectroscopy allows for non-invasive 
determination of tissue properties of intracranial structures, helping differentiate 
between neoplastic and non-neoplastic lesions. MR Perfusion helps visualize blood 
flow to the involved areas [11].
Advances in imaging in the last few decades have led to increasing utilization 
of additional imaging methods. Diffusion tensor imaging (DTI) for evaluating the 
involvement of white matter tracts, can be combined with functional MRI to help 
in preoperative surgical planning. Positron emission tomography (PET) helps to 
visualize small metastases which may be missed, along with helping differentiate 
between normal postoperative changes and residual tumor.
Preoperative biopsy serves as the confirmatory tool in determining the presence 
and the type of tumor. Additionally, in some cases, the preoperative biopsy is not 
performed and diagnosis is made only based on MR imaging, for instance in diffuse 
pontine glioma. In other cases, the imaging allows narrowing down to few differen-
tials, the surgery is begun and intraoperative frozen section is viewed to arrive at a 
tentative diagnosis, after which the definitive surgery is completed.
In addition, coupled with the advent of histo-molecular classification, immu-
nohistochemistry, molecular genetics, and molecular profiling arrays, have all 
become a key tools of management, especially in well-resourced regions globally. 
Methylome profiling, which refers to the utilization of broad arrays to find out 
genome-wide methylation patterns in the DNA, has taken on a greater role as well in 
helping determine an integrated diagnosis and, thereby, provide effective targeted 
treatment. The WHO CNS5 provides for the specific methylation signatures for the 
vast majority of CNS tumors.
Finally, electroencephalography (EEG), audiological and ophthalmological test-
ing, pituitary hormone profile, etc. also are useful tools in the clinician’s armamen-
tarium. Lumbar puncture and CSF analysis also serve as an adjunct in some cases, 
for instance, in the detection of tumor markers in germ cell tumors of the CNS.
5.2 Treatment approaches
3 major anti-cancer approaches, in various combination treatment protocols, 
are the pillars of treatment in pediatric brain tumors: surgery, radiotherapy, and 
chemotherapy. As discussed prior, these three approaches have extremely varying 
efficacy in different tumor types and grades.
5.2.1 Surgery
When undertaken with curative intent, surgery often serves as a major player in 
reducing the bulk of the tumor. It is extremely valuable in tumors with low grade 
e.g. a CNS Tumor Grade 1 Meningioma. However, its utility is reduced in tumors 
that lie close to critical structures such as diffuse pontine glioma.
Surgery may be done through the conventional open approache or a microsurgi-
cal approach or an endoscopic endonasal approach. The latter may prove invaluable 
for selected tumors, as in tumors of the sellar/parasellar region [11]. When resect-
ing a tumor, the surgery may be classified based on the residual tumor into subtotal 
resection, gross total resection, supra-maximal resection, etc. While the subtotal 
approach leaves behind residual neoplastic tissue to avoid damage to critical struc-
tures, a supramaximal resection aims at reducing the tumor burden as much as 
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possible grossly. Global consensus continues to evolve into the exact definition of 
these terms and the varying utility of these different resections in different tumors.
Newer methods are pushing the boundaries of safe and effective surgery. 
Combined with MR Angiography, DTI, and fMRI, along with intraoperative neuro-
monitoring, surgery can be performed in challenging locations, such as those close 
to eloquent areas. Furthermore, awake surgery with intra-operative stimulation 
may be utilized for tumors in eloquent areas in older children [11]. Additionally, 
5-Amino Levulinic Acid (5-ALA) based techniques are allowing better intraop-
erative visualization of residual tumor, thereby assisting in enhanced resection, 
especially in high-grade gliomas.
A small surgical procedure to insert a ventriculoperitoneal shunt remains a key 
measure for alleviating hydrocephalus, which is a common complication of brain 
tumors in the pediatric age group, especially those of the posterior fossa.
5.2.2 Chemotherapy
It finds less value in the brain than in other organs due to the blood–brain barrier 
which prevents adequate permeation of drugs administered. However, it is still a 
useful adjuvant approach for several common pediatric tumors, such as medul-
loblastoma. Notably, intrathecal chemotherapy based on methotrexate and cytara-
bine is significantly useful in intracranial lymphomas/leukemias [12]. The Ommaya 
Reservoir is a useful tool for repeated chemotherapy administration as well as 
repeated CSF withdrawal for either diagnostic and/or therapeutic purposes [13].
5.2.3 Radiotherapy
It has been a cornerstone of preventing recurrence after surgery and in treating 
tumors that are not amenable to resection. It may be given as teletherapy, in the 
form of conventional beam radiotherapy, or can be given as brachytherapy, via 
surgical delivery of emitters into the brain. Radiotherapy is especially valuable in 
tumors with rapidly dividing cells and/or those having high tumor grade. However, 
radiotherapy carries significant risks in the growing brain, where it can adversely 
impact neuronal development and hamper long-term cognitive outcomes. Proton 
therapy, albeit significantly more expensive, is slowly replacing conventional 
photon beam therapy [11].
5.2.4 Newer approaches
In addition, other therapeutic approaches have been coming up but are yet to 
become the standard of care for most tumors. Immunotherapy has been less than 
successful in pediatric brain tumors [14]. Meanwhile, targeted biological therapies 
have found greater utility in specific tumors, such as the role of BRAF-inhibitors in 
tumors with BRAF V600E mutation [15].
5.2.5 Supportive care
Amidst all of this, the role of supportive care, including physiotherapy and 
rehabilitation cannot be understated. Brain tumors rob children of the joy of their 
life and their devastating symptoms cause immense stress to both children and their 
guardians. Corticosteroids for managing cerebral edema, opioids for pain manage-
ment, antiemetics, anticonvulsants for prophylaxis and treatment of seizures, 
baclofen for management of spasticity, adequate nutritional support, psychosocial 




Having covered the general principles of management, this chapter now pro-
ceeds to examine specific brain tumors that have a high burden amongst children.
6. Medulloblastoma
Medulloblastoma (MB) is an embryonal tumor of the cerebellum having discrete 
origins from the neuronal stem or progenitor cell populations during early life. The 
peak age of diagnosis is 6–8 years. MBs are rarely seen in infancy or during adult-
hood [16].
6.1 Epidemiology & genetics
Medulloblastoma is the most common childhood malignancy of the brain 
accounting for 20–30% of all pediatric tumors and 64% of all intracranial embry-
onic tumors [17, 18]. The overall annual incidence rate is approximately 5 cases per 
million, which does not vary substantially across ethnicities or geographical regions 
[19, 20]. The male to female ratio is 1.8:1 [21, 22]. A wide range of syndromes like 
Gorlin syndrome, FAP syndrome, ataxia-telangiectasia, Bloom syndrome, Fanconi’s 
anemia, Li-Fraumeni syndrome and Xeroderma pigmentosum have been implicated 
in MB pathogenesis [23].
Four subgroups of MB have been defined based on the age of onset, genetic 
alterations, and prognosis. These are the WNT subgroup MB (10% of MB), the SHH 
subgroup MB (10–15% of MB), the Group 3 MB (25% OF MB), and the Group 4 MB 
(50% of MB) [23]. Activating mutations of CTNNB1 stabilize Beta-catenin leading 
to the constitutional activation of WNT signaling in 85–90% of the WNT subgroup 
MB, which has a good prognosis in children [24, 25]. Germline/somatic mutations 
in genes of the SHH signaling pathway (PTCH1, SUFU, SMO, GLI1/2, and MYC) 
lead to its constitutional activation in SHH subgroup. MYC activation is character-
istic for Group 3 MB. Several mutations are implicated in Group 4 MB with no clear 
majority, including transcriptional repressors like PRDM6 and histone modifiers 
like KDM6A and KMT2C [26].
6.2 Clinical features
The various manifestations of MB are largely attributed to an increase in ICT and 
cerebellar dysfunction. These include nocturnal or morning headache, nausea, vomit-
ing, and altered mental status. These symptoms evolve over a period of a few weeks to 
months. Specific cerebellar symptoms include ataxia, visual disturbances (eg. strabis-
mus), impacted fine motor skills (eg. clumsy handwriting) that reflect in the patient’s 
school performance [26]. These commmon clinical features may be accompanied by 
syndrome-specific presentations. If spinal drop metastasis has occurred, presenting 
features may include back pain, gait disturbances, bladder and bowel abnormalities. 
The tumor grows rapidly, worsening the symptoms. If accelerated growth occurs 
before 18 months, macrocephalus can delay diagnosis in a subset of children owing to 
the non-fusion of skull sutures [9].
6.3 Diagnosis
The diagnosis of MB is based on clinical features, radiology, and histopathology. 
CSF cytology for microscopic metastasis and molecular analysis for prognostication 
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are done. MRI shows a midline mass involving the vermis or the fourth ventricle, rarely 
seen laterally encroaching the cerebellar hemispheres [27, 28]. T1-weighted imaging 
finds a hypodense to isodense lesion and T2/FLAIR yields a hyperdense tumor. On 
diffusion-weighted imaging, the lesion shows reduced diffusion due to high cellularity 
and nucleus-to-cytoplasm ratio [29]. Imaging the spine is more fruitful in detecting 
drop metastasis than CSF analysis. MB subgroups show characteristic localizations. 
For instance, the WNT subgroup is usually located in cerebral peduncle/cerebellopon-
tine angle, the SHH subgroup in cerebellar hemispheres, the Group 3 and Group 4 MBs 
usually located along the midline with extension into the 4th ventricle [30–32].
Medulloblastoma is a round blue cell tumor, having characteristic microscopic 
appearance. Histopathology and molecular diagnosis distinguish it from other 
posterior fossa tumors like ependymoma, pilocytic astrocytoma, and other embryo-
nal tumors. These reveal a combination of patterns including classic, desmoplastic/
nodular, MB with excessive nodularity, large cell, and anaplastic [33]. A combina-
tion of histologic and genetic variants is integrated for diagnosis.
6.4 Treatment and prognosis
The treatment approach includes a combination of maximal safe surgical resec-
tion, radiotherapy, and systemic chemotherapy [34]. Though gross total resection 
remains the mainstay of surgery, patients with minimal residual tumor can be 
expected to have similar outcomes. The morbidity of a complete resection should 
be adequately assessed by the surgeon against leaving a part of the tumor [35, 36]. 
Since MB usually pushes the vermis in a posterior direction, there are high chances of 
damaging it with tumor removal. Telovelar and transvermian approaches are used to 
preserve vermis and deep cerebellar nuclei as much as possible. Neuronavigation and 
neuroimaging are useful in identifying the anatomy correctly to avoid entry into the 
brainstem and preserve the large draining veins to prevent significant bleeding [37]. 
Complications following resection include cerebellar mutism syndrome or posterior 
fossa syndrome possibly due to splitting of the inferior vermis [38].
Adjuvant radiation therapy is initiated 3–4 weeks after surgery. It should involve 
the entire craniospinal axis and is termed craniospinal irradiation [39]. Focal radia-
tion to surgical bed is not inferior to entire posterior fossa radiation, hence it should 
be preferred due to less exposure. Outcomes that are based on genomic drivers and 
prognostic indicators warrant an individualized approach [36]. Proton beam and 
volumetric arc/ intensity-modulated radiation therapy are being evaluated [39].
Histological subtypes have varying sensitivity for chemotherapy in patients 
<3 years old and ≥ 3 years old groups. Conventional chemotherapy was found suf-
ficient for patients after gross total resection but not with metastasis or incomplete 
resection [40]. However, adjuvant chemotherapy and radiotherapy have better 
outcomes in patients who have undergone partial resection [41].
The overall survival rate is approximately 75% [40]. Age, disseminated or meta-
static disease, residual disease after resection, MYC amplification, and large cell 
anaplastic pathology are all associated with poor prognosis. Infants and children 
less than 3 years of age have a poor prognosis with a 40–50% survival rate [42].
7. Craniopharyngiomas & pituitary tumors
Craniopharyngiomas (CPs) are benign tumors that develop along the hypothal-
amo-hypophyseal tract, constituting 6–9% of pediatric brain tumors [43]. They 
arise from remnants of the Rathke’s pouch - the craniopharyngeal duct epithelium 
and may be sellar or suprasellar [44].
CNS Malignancies
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7.1 Epidemiology & genetics
The incidence of CPs worldwide has been estimated to be 1.33–1.56 per million 
children per year worldwide [45]. In the United States, the incidence is approxi-
mately 2.0–2.3 per million children per year [1], while Japan has a much higher 
incidence of 3.8 per million children per year [20].
There are two histologic subtypes of CPs - papillary CP (PCP) and adaman-
tinomatous (ACP). Both subtypes have highly specific mutations - ACPs are 
characterized by somatic mutations in CTNNB1 (encoding β- catenin) that increase 
β- catenin stability, leading to the activation of the WNT pathway, while PCPs are 
characterized by BRAF V600E mutations. PCPs are mostly restricted to adults, so 
our discussion here will be restricted to ACPs [44].
7.2 Clinical features
Childhood CPs most commonly occur in the age groups of 6–10 years, followed 
by 11–15 years [46]. The diagnosis of CP is usually delayed, even by a few years, 
after symptom onset [47]. Symptoms reflect the location of the tumor, and usually 
progress with time, due to slow growth.
Features by which these tumors of the sellar region clinically present include:
• Headache is seen in approximately half of all CP patients [47, 48].
• Endocrine deficiencies due to disturbances of the hypothalamo-hypophyseal 
tract - diminished growth hormone (GH), gonadotropin, thyroid-stimulat-
ing hormone (TSH), or adrenocorticotropic hormone secretion (ACTH), 
in that order of frequency [44]. In children, this most commonly manifests 
as growth failure. Central diabetes insipidus is also common. At least one 
endocrine deficit as the first symptom is reported in nearly 87% of all 
cases [44]
• Visual deficits - symptoms are present, or deficits are unearthed on formal 
ophthalmologic examination, in 70–80%. The classical bitemporal hemianopia 
is seen in about half the cases [43].
• Others - depression, regardless of any hormonal deficiency, may occur [48]. 
Diencephalic syndrome leading to cachexia is a rare manifestation [44].
7.3 Diagnosis
A simple rule of thumb is that nearly 90% of pediatric CPs demonstrate calcifica-
tion, approximately 90% of tumors are predominantly cystic, and about 90% take up 
the contrast in the cyst walls [47] CT remains the gold standard for the identification 
of calcifications [44]. The mixed solid and cystic components appear hypodense com-
pared to surrounding cerebral parenchyma. Fluid within the cysts will be of slightly 
greater density than cerebrospinal fluid due to the higher protein content. CT can also 
illustrate secondary skull base changes useful for surgical planning [43].
MR Imaging and MR Angiography provide greater clarity regarding the 
relationship of the tumor with vascular structures. MR spectroscopy (MRS) can 
identify characteristic elevated peaks of lactate or lipids, to differentiate them 
from gliomas and pituitary adenomas [43]. Finally, an endocrinological evalua-
tion also reveals deficient hypothalamic function, which is particularly relevant 
preoperatively [43].
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7.4 Treatment & prognosis
Each case must be decided on its own merit [43] as there is no consensus. 
Surgery is indicated in almost all cases. Two broad approaches are used - aggressive 
surgery at diagnosis, or more conservative surgery with radiotherapy [48].
The choice of surgical approach i.e. endoscopic or open or combined depends 
on the surgeon’s level of comfort, and the location of the tumor. Teams that prefer 
limited surgical resection only use surgery to alleviate visual or other neurologic 
deficits, and prevent further progression, with RT used for long-term control. 
Proton beam therapy for CP has shown great promise [47]. For cysts specifically, 
repeated aspiration and/ or injection of a sclerosant, or local radiation may be 
attempted [44, 47, 48]. These may help in postponing RT, particularly in younger 
children [44].
Postoperative sequelae include panhypopituitarism and hypothalamic obesity, 
which can be challenging to treat [48]. Others include neurocognitive deficits, sleep 
disorders, and exacerbated visual deficits [48]. Patients remain at greater risk of 
ischemic stroke, and secondary malignancy owing to radiation exposure.
Overall, the survival rates are high, around 90%, but due to postoperative 
sequelae, quality of life is impaired [49]. With recent advances clarifying the patho-
genesis of adamantinomatous CPs, there is hope for the development of targeted 
therapies [50].
8. Astrocytoma
Astrocytoma is a tumor arising from the astrocytes, which are a type of glial cells 
found in the central nervous system (CNS).
8.1 Epidemiology & genetics
According to the WHO CNS5 classification, astrocytomas (IDH mutant) are 
categorized under the broad heading of adult-type diffuse gliomas. Meanwhile 
diffuse astrocytomas (MYB or MYLB-1 altered) are classified into pediatric type 
diffuse low-grade gliomas; circumscribed astrocytic glioma encompasses pilocytic 
astrocytoma, high-grade astrocytoma with piloid features, pleomorphic xantho-
astrocytoma, subependymal giant cell astrocytoma, choroid glioma and astroblas-
toma (MN1-altered) [34]. Astrocytomas do not have any racial or ethnic inclination 
and are usually sporadic.
8.2 Clinical features
Clinical features include headache, seizures, and focal neurological deficit, as 
discussed in previous tumors [51]. In few cases, these tumors may be associated 
with Li-Fraumeni syndrome and Lynch syndrome.
8.3 Diagnosis
Contrast-enhanced MRI is the mainstay of diagnosis. High-grade gliomas are usually 
associated with hypointensity on T1-weighted imaging and heterogenous contrast-
enhancement. They have increased choline and reduced N-acetyl aspartate on magnetic 
resonance spectroscopy due to their higher vascularity as well as increased metabolism 
[52]. Histologically, astrocytomas include cells with irregular, hyperchromatic nuclei 
and glial fibrillary acidic protein (GFAP) in the cytoplasm, and increased mitotic 
CNS Malignancies
12
activity. Molecular testing plays a key role in the diagnosis, treatment, and prognosis of 
the patient [52, 53]. IDH mutation testing and, 1p/19q codeletion testing is done.
8.4 Treatment
Treatment in most cases is a combination of surgery followed by radiotherapy. 
Surgery for astrocytoma has benefitted greatly from recent advances, including 
5-ALA based resection, awake surgery, intraoperative stimulation, and neuronavi-
gation, allowing for tumor resection close to eloquent structures and critical vessels.
9. Ependymomas
Ependymomas are a subset of glial tumors arising from radial glial cells in the 
subventricular zone, located in or adjacent to the ependymal lining. Most com-
monly, they are associated with the fourth ventricle [54].
9.1 Epidemiology & genetics
Ependymomas account for 10% of all brain tumors making them the third most 
common intracranial pediatric malignancy, with a sex ratio of 1.77:1 [54]. The 
annual incidence rate amongst children is 0.46 per million in the United States [1].
WHO classifies ependymomas according to a combination of histopathological 
and molecular features into supratentorial ependymomas with ZFTA, RELA, YAP1 
or MAML2 mutation, posterior fossa ependymomas with H3K27-mutation, EZHIP 
mutations, and spinal ependymomas with NF2, MYCN mutations. Molecular 
classification of myxopapillary ependymoma and subependymoma do not add to 
clinical utility, hence they are studied as separate entities [7].
9.2 Clinical features
The age and the site of origin determine presentation. Failure to thrive, leth-
argy, and irritability like non-specific clinical features are observed in very young 
children. Posterior fossa tumors present with increased intracranial pressure, nerve 
palsies, neck pain, and/or ataxia. Supratentorial tumors present with limb weak-
ness, bowel bladder dysfunction, paraesthesia, and pain [55].
Seizures with or without focal neurological deficits are also commonly seen in 
supratentorial tumors. This may be due to the surrounding edema and mass effect. 
Spinal cord tumors involve ascending or descending tracts and manifest as specific 
anatomical lesions. Very rarely, CSF seeding may accompany both infratentorial 
and supratentorial ependymomas [56].
9.3 Diagnosis
The imaging modality of choice is an MRI scan of the brain and spine to evaluate 
for leptomeningeal dissemination [57]. T1 hypointensity and T2 hyperintensity with 
heterogeneous enhancement on T1 sequences post-gadolinium enhancement is seen in 
both spinal and intracranial tumors. Cysts and calcification can be observed, usually 
with supratentorial tumors. Spinal ependymomas can be differentiated from astrocy-
tomas by a sharp margin and central location. Leptomeningeal spread can be suspected 
by smooth enhancement along the surface of the spinal cord, nerve root thickening, or 
irregular thecal sac, and confirmed by cytological assessment post lumbar puncture. 
Testing for the mutations discussed prior can be done if resources are available.
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9.4 Treatment & prognosis
Pediatric ependymomas are treated with surgery and radiotherapy [58]. The 
surgeon’s decision about the extent of resection is the most important prognostic 
factor. Posterior fossa tumors may limit the extent of resection due to involvement 
of lower cranial nerves and brainstem, thus incomplete resection warrants a second 
look surgery since overall survival for incomplete resection is much lower than 
gross total resection [59].
Postoperative radiotherapy is recommended for children as young as 18 months 
but dose modifications to reduce toxicity should be done [60]. Hypofractionated 
stereotactic boost in addition to conventional radiotherapy, especially for incom-
plete surgery, is being studied and shows promise [59]. To avoid radiation exposure 
to children, chemotherapy use has been investigated but its role remains equivocal 
[61]. Though long-term follow-up studies of radiotherapy toxicity are pending, the 
higher progression-free survival with radiotherapy has led to the abandonment of 
radiotherapy deferral strategies for children below 12 months [62].
Patients with intracranial ependymomas usually have a significant risk of recur-
rence and decreased 5-year overall survival, nearing approximately 50–70% [62].
10. Germ cell tumors
According to the W.H.O. CNS tumor 2021 classification, germ cell tumors are 
classified into mature teratoma, immature teratoma, teratoma with somatic-type 
malignancy, germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, 
and mixed germ cell tumor [34].
10.1 Epidemiology & genetics
The incidence of all types of CNS germ cell tumors (GCT) is greater in males of 
10–14 years of age. These tumors also possess a racial inclination towards Asians 
and Pacific Islanders [63]. Although GCTs can arise anywhere in the CNS, the 
pineal gland is most commonly involved, followed by the suprasellar/ neurohy-
pophyseal area and the basal ganglia. A bifocal tumor is one where both the pineal 
gland and the neurohypophyseal region are involved [64].
10.2 Clinical features
Obstructive hydrocephalus can result from the compression of the cerebral 
aqueduct by the tumor, often manifested as headache [65]. The damage to the 
optic nerve due to the mass effect of the tumor can cause visual field defects and 
decreased visual acuity [66]. Neurophypophyseal tumors can often lead to hypo-
pituitarism, diabetes insipidus [66]. GCT of the basal ganglia can present with 
hemiparesis. Intracranial hemorrhage is also a complication of GCTs [66]. Due to 
the involvement of the optic nerve, often the ophthalmologists are the first ones to 
interact with the patients of CNS GCT, and play a crucial role in the diagnosis.
10.3 Diagnosis
The tumor markers associated with CNS GCTs are the following: beta subunit of 
human chorionic gonadotropin (β -HCG), alpha-fetoprotein (AFP), and placental 
alkaline phosphatase, which are raised in different types of GCTs differently. In 
choriocarcinoma, the β-HCG value is >500 mIU/mL, while in germinoma with 
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syncytiotrophoblastic giant cells, β-HCG is <100 mIU/mL. β-HCG is also increased in 
mixed germ cell tumors. AFP is raised in yolk sac tumors and mixed germ cell tumors.
The findings on imaging include a typical pineal mass on MRI or CT, usually 
with calcifications, and signs of obstructive hydrocephalus on CT. Germinomas 
are generally of uniform intensity with blurred margins. Pineal teratomas appear 
as heterogeneous well-demarcated masses with occasional calcifications, irregular 
cysts, or fatty tissue and thus show a peculiar pattern on both CT and MRI [64]. For 
GCTs occurring in the basal ganglia, enhancement is minimal, and the only detect-
able abnormality is an occasionally increased signal intensity on FLAIR [64].
10.4 Treatment & prognosis
According to the Japanese Pediatric Brain Tumor Study Group, patients with 
CNS non-seminamatous GCT may be divided into three categories (based on their 
prognosis): good (mature teratoma and pure germinoma), intermediate (e.g. imma-
ture teratoma), and poor (e.g. choriocarcinoma, yolk sac tumor). The 5-year overall 
survival rate varies as per the histologic type from 10 to over 98%. As for non-
seminomatous germ cell tumors, the group reported a 5-year survival rate of 67% 
with platinum-based chemotherapy followed by surgical resection and craniospinal 
irradiation together with focal boost [67, 68].
11. Brain stem gliomas
Brainstem gliomas constitute 10–20% of all pediatric CNS malignancies and 
can be broadly divided into focal brainstem gliomas (FBGs) and diffuse intrinsic 
pontine gliomas (DIPGs) [1, 69].
11.1 Epidemiology & genetics
11.1.1 FBG
FBGs usually arise in the midbrain or the medulla and are well-circumscribed, 
low-grade tumors – usually being pilocytic or diffuse astrocytomas. These may 
be associated with Neurofibromatosis 1 (NF1). Characteristic mutations include 
chromosome 7q34 duplications, resulting in a KIAA1549-BRAF fusion, in pilocytic 
astrocytomas, and a BRAF V600E mutation in fibrillary astrocytomas, the majority 
of pleomorphic xanthoastrocytomas, and nearly half of the gangliocytomas [69–71].
11.1.2 DIPG
DIPGs constitute 80% of all pediatric brainstem tumors and are diffuse, high-
grade, and infiltrative. 80% of these have H3K27 mutations on two histone H3 
genes, identified primarily through autopsy studies [69]. EGFR mutations are also 
common [72]. Histologically, these are usually high grade, although a significant 
proportion may appear low grade, which is ultimately irrelevant for prognosis.
11.2 Clinical features
11.2.1 FBG
These usually present insidiously over many years [69–71]. Isolated cranial nerve 
deficits, neck stiffness, and pain, contralateral hemiparesis are common [69–71]. 
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Medullary tumors may cause dysphagia or apnea, while cervicomedullary tumors 
may present with ataxia and/ or lower motor neuron signs. Hydrocephalus is uncom-
mon, except in posteriorly extending tumors and tumors of tectal origin [69–71].
11.2.2 DIPG
Patients typically present around the age of 7 years, with a short history, 
sometimes for less than a month [69, 73, 74]. The classical triad of (1) cranial 
nerve palsies, most commonly VI and VII - facial asymmetry and diplopia (2) 
long tract signs - upgoing Babinski, and hyperreflexia, and (3) cerebellar signs - 
ataxia, dementia is seen in over 50% [73]. Symptoms and signs of raised ICT are 




On MRI, these usually have well-defined borders, no edema, iso- or hypointen-
sity on T1, and hyperintensity on T2 weighted images, with homogeneous contrast 
enhancement [69–71]. MR Spectrography can support the diagnosis, with the esti-
mation of choline-to-N-acetylaspartate (Choline:NAA) ratios differentiating high 
grade from low-grade tumors. Diffusion Tensor Imaging (DTI) can also provide 
estimates of long tract disruption [69].
11.3.2 DIPG
DIPGs are typically hypointense on T1 and hyperintense on T2 weighted MRI 
[69, 73]. Contrast enhancement is variable. A diffuse expansion of the pons is 
typical. This may involve adjacent areas, such as the cerebellum and midbrain; the 
medulla is usually spared [69–71] There is usually an exophytic component, and the 
tumor may surround the basilar artery. However, a serial assessment may be dif-
ficult due to their heterogeneous signal characteristics and interobserver variability. 
Here too, MR spectrography with Choline:NAA ratio estimation can support the 
tentative diagnosis and may provide prognostic information [71].
11.4 Treatment & prognosis
11.4.1 FBG
In surgically accessible regions, resection is performed. While complete resec-
tion is curative, it should not be performed at the cost of neurologic deficit, as even 
incomplete resection has excellent long-term outcomes [75].
Chemotherapy is preferred for inoperable tumors, symptom progression, or 
persistence after surgery. Tumor growth can at least be stabilized, delaying or even 
eliminating the need for RT in young children [69–71]. Two popular, effective 
combinations are that of vincristine and carboplatin, and another of 6-thiogua-
nine, procarbazine, lomustine, and vincristine (TPCV) [69]. TPCV has improved 
progression-free survival, but carries long-term risks associated with alkylator use 
[69]. Radiotherapy is an option for surgically inaccessible tumors but should be 
reserved for older children given the potential for significant morbidity [69–71]. 
Long-term overall survival approaches 100% [70], but chronic disability is com-




Surgery is usually not recommended [71]. The mainstay of treatment is frac-
tionated radiotherapy alone [73]. There is still uncertainty regarding the mode of 
RT to be delivered, with future trials comparing fractionated and conventional 
RT encouraged [76]. Monotherapy or combination chemotherapy have proven 
ineffective.
With greater clarity regarding the genetic make-up and microenvironment of 
these tumors, immunotherapy and molecular targets, such as anti-GD2 chimeric 
antigen receptor (CAR) T-cell therapy and histone deacetylase (HDAC) inhibitors 
are showing promise [71, 73].
The prognosis remains dismal, with less than 3% surviving at 5 years 
[71]. Long-term survivors usually have neurological deficits and cognitive 
 impairment [76].
12. Meningiomas
Meningiomas arise from arachnoidal cap cells in CNS.
12.1 Epidemiology & genetics
They are rare in children, representing only 2–3% of pediatric CNS tumors 
[77]. Their incidence is markedly greater in syndromes like Neurofibromatosis 
2, Schwannomatosis, Gorlin syndrome, and familial meningioma syndrome 
[77, 78]. Exposure to irradiation in childhood predisposes to the development of 
meningiomas [77, 78].
12.2 Clinical features
Mostly, they present in the second decade of life [78] The most common pre-
senting symptoms are headache, seen in almost half, followed by seizures, seen 
in almost 30%. Focal findings such as visual deficits, cranial nerve signs may also 
be present.
12.3 Diagnosis
CT and MRI demonstrate a well-defined, extra-axial, dural-based mass, that 
displaces the normal brain. It is isointense or hypointense to gray matter on T1 and 
isointense or hyperintense on T2-weighted images [77]. Contrast enhancement is 
strong and uniform on both CT and MRI [78]. On histology, most are WHO Grade 
I. The best-characterized mutation is that of the NF2 gene, with other molecular 
mechanisms in the pediatric age group poorly characterized. Tumors in this age 
group are genetically distinct from their adult counterparts [78].
12.4 Treatment & prognosis
Symptomatic meningiomas require resection. The extent of initial resection is 
a prognostic factor, so total resection must be done where possible. Adjuvant RT 
is recommended for WHO Grade III tumors, while inoperable WHO Grade I and 
Grade II tumors require a case-by-case consideration [78]. The 5-year survival is 
approximately 90%. Those who undergo gross-total resection, those without NF2, 
and those with lower-grade tumors have higher survival rates.
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13. Schwannoma
Schwannomas or neurilemmomas are tumors originating from schwann cells 
around the axons of the cranial nerves. They are encapsulated and do not transform 
into malignancies [79].
13.1 Epidemiology & genetics
Though schwannomas are more commonly seen in adults between the ages of 
50-60 years, 89% of nerve sheath tumors are schwannomas even in children [79], 
the incidence of which is 0.44 cases per 100,000/ year [80, 81]. Most (90%) of the 
schwannomas are sporadic and others occur as part of syndromes like NF2 and 
Carney complex. Inactivation of gene NF2 coding for the merlin protein (schwan-
nomin) has been implicated in both sporadic and syndromic schwannomas. Spinal 
schwannomas may have SMARCB1 mutations [82].
13.2 Clinical features
These tumors grow slowly and may present much later with location-specific 
symptoms. Vestibular schwannomas may present with headache, imbalance, tin-
nitus, cranial nerve deficits and motor weakness. Spinal schwannomas may present 
with pain, paresthesia, and/or motor weakness [83].
13.3 Diagnosis
MRI is preferred over CT for diagnosis since plain radiographs are not specific. 
They usually show an oval or round mass with an isointense or hypointense signal 
on T1 and hyperintense, heterogeneous signal on T2 images [82]. Classically, micro-
scopic findings include Antoni A and Antoni B areas, with Verrocay Bodies.
13.4 Treatment and prognosis
The benign course of these tumors may allow for observation and serial MRI 
scans for periodic assessment. Biopsy to confirm histology before resection is 
recommended. Surgical approaches include the retro-sigmoid, middle fossa, or 
translabyrinthine approach [84]. Stereotactic radiosurgery may be of benefit if 
complete resection cannot be done. Usually, these tumors have an excellent progno-
sis, however, postoperative complications which are more common in the pediatric 
population may worsen it [85].
14. Other tumors
14.1 Choroid plexus tumor
Choroid plexus tumors arise from neuroepithelial tissue that makes CSF in the 
ventricles, and therefore their distribution corresponds to the amount of the cho-
roid plexus present in different ventricles [86]. Nearly 50% occur in the lateral ven-
tricles, 40% in the 4th ventricle and merely 5% in the third ventricle. Meanwhile, 
multifocal occurrence is seen in around 5% of tumors. Overall, they are merely 1% 
of all pediatric brain tumors, but make up 15% of tumors in children aged <1 year. 
Headache and/or hydrocephalus are two common clinical presentations [87].
They are of two major varieties:
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14.1.1 Choroid plexus papilloma (CPP)
These are likely hamartomas and therefore appear similar to normal choroid 
plexus tissue histologically. Classified as WHO grade I in general, they contain 
uniform cellularity with little/no atypia and KI-67 index <2%. Atypical CPPs have 
higher mitotic count (≥2 mitoses/high power field) and are classified as grade II 
[86]. They are calcified and enhance with contrast. On MR imaging they have flow 
voids due to their vascularity, with enlarged choroidal arteries on MR angiography. 
Asymptomatic tumors can be monitored conservatively and only resected if pro-
ducing symptoms or enlarging. Surgery is the modality of choice for symptomatic 
and/or large CPPs. Adjuvant radiotherapy is usually not required and prognosis is 
excellent, with 10-year survival exceeding 80% [88, 89].
14.1.2 Choroid plexus carcinoma (CPC)
These are rarer than CPPs and can be a part of manifestation of Li-Fraumeni 
Syndrome. They are aggressive tumors, with their invasion making gross total 
resection insufficient. Radiotherapy is useful but prognosis is poor with median 
survival of <3 years [87].
14.2 Atypical teratoid/rhabdoid tumor
These are highly aggressive tumors which occur in children <3 years of age, 
with nearly two third occurring in the cerebellum, and nearly a fourth being 
supratentorial.
These have specific diagnostic criteria, of which the characteristic ‘Rhabdoid 
Cells’ are not a part. The criteria are (A) loss of INI1 nuclear staining (correspond-
ing to biallelic inactivation of SMARCB1) and (B) loss of BRG1 staining (cor-
responding to inactivation of SMARCB4) [90, 91]. On MRI, they are hypo-intense 
on both T1 and T2, with several cysts and hemorrhages, leading to a heterogeneous 
appearance. Leptomeningeal enhancement may be visualized. Surgery has little role 
here. Combination chemotherapy followed by radiotherapy is utilized but is chal-
lenging to implement given the very young age of patients at the time of diagnosis. 
Therapy has to be closely matched to the child’s age, AT/RT’s location, and disease 
extent [92]. Prognosis is unsatisfactory, with nearly 30% 5-year survival [93].
14.3 Neuronal and mixed neuronal-glial tumors
Neuroepithelial tissues in the CNS give rise to mixtures of glial and/ or neuronal 
differentiated tumors. These are rare tumors in children.
14.3.1 Ganglioneuromas
These account for 0.3–1.4% of all CNS tumors, usually occurring in adoles-
cents [94]. Focal motor seizures are the most common presentation involving the 
temporal lobe [95]. They are diagnosed by MRI and gross total resection is usually 
preferred for better survival rates [94].
14.3.2 Desmoplastic infantile ganglioglioma or desmoplastic infantile astrocytoma
They are supratentorial cystic tumors usually affecting children less than 2 years 
[96]. Frontal and parietal lobes are the most common locations which present as 
head enlargement, seizures, vomiting, and headache are observed. Diagnosed with 
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MRI, they are slow-growing tumors. They have a good prognosis after complete 
removal, rarely requiring radiotherapy and chemotherapy [97].
14.3.3 Dysembryoplastic neuroepithelial tumor
These tumors cause early-onset epilepsy in children with an incidence of 0.03 
person-year per 100,000 and have slight male predominance [98]. The mesial tem-
poral lobe is the most common location identified on imaging. Favorable outcomes 
are reached in 70–90% of cases after complete resection [99].
14.3.4 Papillary glioneuronal tumor
Characterized by papillary architecture and bipartite (astrocytic and neu-
rocytic) cellularity, these tumors mostly occur near the lateral ventricles [100]. 
Imaging shows them as circumscribed lesions with frequent cystic alterations. 
Patients are either asymptomatic or complain of mild symptoms. Their benign 
course rarely warrants complete resection [101].
14.3.5 Rosette-forming glioneuronal tumor
Usually seen in children above 6 years of age, with a female predominance, their 
location in the 4th ventricle is one of the defining features [102]. Headache, nausea/
vomiting, ataxia, and visual disturbances are common manifestations. MRI reveals 
solid or cystic or mixed solid and cystic masses rarely with calcifications. Full resec-
tion prevents recurrence [102].
14.3.6 Myxoid glioneuronal tumor
These are extremely rare tumors. They present as seizures and other focal 
deficits. A histopathological feature of myxoid stroma, somatic next-generation 
sequencing showing PDGFRA gene mutation, and MRI findings help in diagnosis. 
They have a benign course [103].
14.3.7 Diffuse leptomeningeal glioneuronal tumor
These tumors have variable neuronal components including neurocytes and 
ganglion cells [104]. The median age of presentation is five years with slight female 
predominance [105]. MRI shows meningeal enhancement in spinal cord and basilar 
[106]. Symptoms mimic meningitis and hydrocephalus. Chemotherapy and radio-
therapy are first-line options [107].
14.3.8 Gangliocytoma
These account for 1–5% of all pediatric CNS tumors [108]. Majority of them 
occur in the temporal lobe, causing epilepsy, varied neurological signs/symptoms 
including cranial nerve deficits, focal weakness, and hydrocephalus [109]. Gross 
total resection yields a good prognosis.
14.3.9 Multinodular and vacuolating neuronal tumor
Very few cases have been reported diagnosing this new entity. Non-specific clinical 
features like chronic headache, paresthesias, and cognitive impairment are reported. 
MRI is used for diagnosis and studies of treatment modalities are yet unavailable [110].
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14.3.10 Dysplastic cerebellar gangliocytoma or Lhermitte-Duclos disease
This is a rare entity in children that mimics low-grade glial tumors or infectious 
diseases. A slow-growing pattern and late clinical manifestations allow for conser-
vative treatment and outpatient follow-up for asymptomatic children [111].
14.3.11 Neurocytomas
Depending on their location, these are divided into central, extraventricular, 
and cerebellar. They often mimic oligodendrogliomas and the confirmation of diag-
nosis rests on immunohistochemistry, histology and genetic studies. Safe maximal 
resection is considered the ideal option for a good prognosis. Adjuvant radiotherapy 
benefits incomplete resection [110].
14.4 Hemangiomas
Infantile CNS hemangiomas are rare benign tumors composed of endothelial 
cells. They are seen in about 1% of children with cutaneous hemangiomas and have 
a female predilection [112, 113]. They may be associated with PHACES (posterior 
fossa malformations, hemangioma, arterial anomalies, coarctation of the aorta/
cardiac defects, and eye abnormalities) syndrome, and are more common in the 
posterior fossa [112]. GLUT1 represents a reliable marker. They have a rapid, early 
stage of proliferation followed by one of involution that usually extends from 1 year 
of age to 5 to 7 years of life [112]. Many are asymptomatic or undiscovered, but oth-
ers can present with seizures, focal deficits, or symptoms of raised ICP [112].
During the proliferative phase, CT and MRI show a well-circumscribed lobular 
homogeneous soft-tissue mass with intense and persistent enhancement, with Doppler 
showing features of fast flow. In the involuting phase, they enhance to a lesser degree, 
have fewer radiographic signs of fast-flow vascularity, and appear heterogeneous. The 
final involuted phase is represented by fibrofatty tissue [112]. Imaging can establish 
continuity between the CNS tumor and the extra CNS component. Corticosteroids 
represent the mainstay of treatment. Interferon-alpha and propranolol may also be 
used [112]. For biopsy, or mass effect alleviation, excision may be tried.
15. Conclusions
Pediatric brain tumors have an immense disease burden, given their status as 
the most common solid organ tumors of children. The WHO 2021 Classification is 
a landmark change in the approach to diagnosing and treating these tumors. The 
landscape of their treatment has been rapidly evolving, with effective therapies on 
the horizon. In current clinical practice, surgery, radiotherapy and chemotherapy 
continue to be the mainstay of management.
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